Determination of Regulatory Review Period for Purposes of Patent Extension; JEMPERLI

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for JEMPERLI, a human biological product, following a submission to the US Patent and Trademark Office (USPTO) for patent extension. The FDA is publishing this notice as required by law.